ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

SEC Charges Biotech Firm With Fraud

by Marc S. Reisch
August 15, 2011 | APPEARED IN VOLUME 89, ISSUE 33

The Securities & Exchange Commission has filed a complaint in federal court against biopharmaceutical firm Immunosyn, three shareholder companies, and four senior executives. The complaint charges Immunosyn with misleading investors about the regulatory status of SF-1019, a goat-blood-derived biological response modifier being developed by Argyll Biotechnologies, its controlling shareholder. It also charges the executives with making $20 million in insider-trading profits. SEC wants to force the executives to return their profits and pay penalties and to bar them from serving as officers of a public company.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment